February 23, 2023

Covid-19 Therapeutics

The Case for Antiviral Treatment

There is strong scientific evidence that antiviral treatment of outpatients at risk for severe COVID-19 reduces their risk of hospitalization and death. Some people from racial and ethnic minority groups are at increased risk of complications from COVID-19 infection. Other risk factors include:

Age over 50 years, with risk increasing substantially at age ≥ 65 years
Being unvaccinated or not being up to date on COVID-19 vaccinations
Specific medical conditions and behaviors

Read More from the CDC

Weekly COVID-19 Snapshot

Check Your Community's Stats

Download these resources to support your work:

Attend an upcoming educational session to learn more:

Boosters & Beyond: Addressing Key Challenges - CDC's Core IP Practices - Environmental Cleaning & Disinfection. February 28 at 12 noon.

Next week we are offering a number of programs on Heart Health, Pneumonia, CDC practice, CLAS, Health Equity, and Workforce - please visit our calendar to learn more and sign up for those of interest.

Visit our website
Email us
Call us toll-free at 888-502-0566

Visit Our Resource Library

Join Our Network

www.qi.ipro.org

The IPRO QIN-QIO works to ensure high-quality, safe health care in New England, New York, New Jersey, Ohio, Delaware, Maryland, and the District of Columbia.

This material was prepared by the IPRO QIN-QIO, a Quality Innovation Network-Quality Improvement Organization, under contract with the Centers for Medicare & Medicaid Services (CMS), an agency of the U.S. Department of Health and Human Services (HHS). Views expressed in this document do not necessarily reflect the official views or policy of CMS or HHS, and any reference to a specific product or entity herein does not constitute endorsement of that product or entity by CMS or HHS. 12SOW-IPRO-QIN-T1-AA-21-435